Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

THE RELATIONSHIP between biologic therapies and the risk of major adverse cardiovascular events (MACEs) and venous ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 ...

Professor Martin Röcken discusses challenges and opportunities in dermatology care, immunotherapy, the MDT and his hopes for ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit ...